文献速递慢性肾脏病血液净化与透析

CKD患者血管通路转诊策略的成本效果分析

Cost-effectiveness Analysis of Vascular Access Referral Policies in CKD.
PubMed 文献 · Am J Kidney Dis · 2017-06-07

该研究采用蒙特卡罗模拟模型,在终身时间跨度内从支付者角度评估CKD患者不同血管通路转诊策略的成本效果。HD前转诊AVF或AVG优于延迟至HD开始。成本效果主要受HD年成本、促红细胞生成素成本和患者效用值影响。

要点

  • HD前转诊AVF或AVG优于延迟至HD开始。

核心结论

  • 血管通路转诊的成本效果主要由HD年成本、促红细胞生成素成本和通路相关效用值驱动。
  • HD前转诊AVF或AVG优于延迟至HD开始。

研究设计与样本

  • 蒙特卡罗模拟模型,成本效果分析,支付者角度,终身时间跨度。
  • 对象为转诊至多学科肾脏门诊的CKD患者,处于全民医疗体系。

主要发现

  • HD前转诊AVF或AVG优于延迟至HD开始。
  • HD前转诊的ICER随患者年龄增加而升高。
  • 结果对促红细胞生成素成本、持续HD成本和患者HD效用值最敏感。

关键数值与推荐

  • 当分析中排除持续HD成本时,HD前转诊AVF优于HD前转诊AVG和仅用CVC策略。

临床怎么用

  • 对于可能需HD的CKD患者,可考虑在预测HD开始前12个月转诊AVF或前3个月转诊AVG。
  • 决策时应考虑患者年龄,年龄越大成本效果越差。
  • 应关注促红细胞生成素成本和HD相关生活质量对成本效果的影响。

局限性

  • HD、AVF和AVG的效用值基于文献估计,存在局限性。
  • 需要进一步研究透析相关生活质量以辅助血管通路转诊决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal timing of vascular access referral for patients with chronic kidney disease who may need hemodialysis (HD) is a pressing question in nephrology. Current referral policies have not been rigorously compared with respect to costs and benefits and do not consider patient-specific factors such as age. STUDY DESIGN: Monte Carlo simulation model. SETTING & POPULATION: Patients with chronic kidney disease, referred to a multidisciplinary kidney clinic in a universal health care system. MODEL, PERSPECTIVE, & TIMEFRAME: Cost-effectiveness analysis, payer perspective, lifetime horizon. INTERVENTION: The following vascular access referral policies are considered: central venous catheter (CVC) only, arteriovenous fistula (AVF) or graft (AVG) referral upon HD initiation, AVF (or AVG) referral when HD is forecast to begin within 12 (or 3 for AVG) months, AVF (or AVG) referral when estimated glomerular filtration rate is <15 (or <10 for AVG) mL/min/1.73m2. OUTCOMES: Incremental cost-effectiveness ratios (ICERs, in 2014 US dollars per quality-adjusted life-year [QALY] gained). RESULTS: The ICER of AVF (AVG) referral within 12 (3) months of forecasted HD initiation, compared to using only a CVC, is ∼$105k/QALY ($101k/QALY) at a population level (HD costs included). Pre-HD AVF or AVG referral dominates delaying referral until HD initiation. The ICER of pre-HD referral increases with patient age. Results are most sensitive to erythropoietin costs, ongoing HD costs, and patients' utilities for HD. When ongoing HD costs are excluded from the analysis, pre-HD AVF dominates both pre-HD AVG and CVC-only policies. LIMITATIONS: Literature-based estimates for HD, AVF, and AVG utilities are limited. CONCLUSIONS: The cost-effectiveness of vascular access referral is largely driven by the annual costs of HD, erythropoietin costs, and access-specific utilities. Further research is needed in the field of dialysis-related quality of life to inform decision making regarding vascular access referral.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Shechter SM, Chandler T, Skandari MR, et al. Cost-effectiveness Analysis of Vascular Access Referral Policies in CKD. Am J Kidney Dis. 2017. PMID: 28599902. doi:10.1053/j.ajkd.2017.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。